Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) insider Harpreet Dhaliwal sold 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $67.83, for a total value of $1,153,110.00. Following the sale, the insider directly owned 68,085 shares in the company, valued at approximately $4,618,205.55. The trade was a 19.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vaxcyte Stock Performance
PCVX opened at $63.37 on Monday. The business has a 50 day moving average price of $62.24 and a two-hundred day moving average price of $57.65. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.56 and a quick ratio of 4.56. The company has a market capitalization of $10.03 billion, a price-to-earnings ratio of -7.86 and a beta of 1.31. Vaxcyte, Inc. has a 1-year low of $42.40 and a 1-year high of $90.75.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same period last year, the firm earned ($1.56) EPS. Research analysts predict that Vaxcyte, Inc. will post -7.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on PCVX. Bank of America decreased their target price on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research note on Monday, September 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $120.00 price target on shares of Vaxcyte in a research report on Monday, October 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, October 2nd. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.50.
Get Our Latest Stock Analysis on Vaxcyte
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc lifted its position in shares of Vaxcyte by 72.8% during the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after acquiring an additional 236 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of Vaxcyte by 398.7% during the 3rd quarter. Global Retirement Partners LLC now owns 773 shares of the company’s stock worth $44,000 after acquiring an additional 618 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Vaxcyte in the 3rd quarter worth $47,000. Manchester Capital Management LLC acquired a new position in shares of Vaxcyte in the 3rd quarter worth $47,000. Finally, Covestor Ltd grew its holdings in shares of Vaxcyte by 31.1% in the 3rd quarter. Covestor Ltd now owns 939 shares of the company’s stock worth $53,000 after acquiring an additional 223 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.
Vaxcyte Company Profile
Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.
Recommended Stories
- Five stocks we like better than Vaxcyte
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
